Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774459 | PMC |
| http://dx.doi.org/10.1007/s13181-023-00983-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
How to Put Survival After Cardiothoracic Interventions in the General Population Context: A Case-Based Practical Guideline to Calculate Cumulative Matched-General-Population Survival.
Circ Cardiovasc Qual Outcomes
January 2025
Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands. (X.W., M.L.N., K.M.V., P.G., J.R.G.E., A.J.J.C.B., J.J.M.T.).
Background: Observed patient survival after cardiothoracic interventions should ideally be placed in the context of matched-general-population survival. This study outlines several methodologies of matching general population mortality to the study sample, subsequently calculating cumulative matched-general-population survival, highlighting their respective advantages, disadvantages, and limitations.
Methods: A multicenter data set containing survival data after the Ross procedure was used for methodological illustration.
Recreational and Occupational Physical Activity and Risk of Adverse Events in Truncating Founder Variant Carriers.
Circ Genom Precis Med
December 2024
Department of Cardiology (M.J., L.P.B., A.F.S., D.v.d.S., A.S.J.M.t.R.), University Medical Center Utrecht, Utrecht University, the Netherlands.
Background: founder variants cause hypertrophic cardiomyopathy leading to heart failure and malignant ventricular arrhythmias. Exercise is typically regarded as a risk factor for disease expression although evidence is conflicting. Stratifying by type of exercise may discriminate low- from high-risk activities in these patients.
View Article and Find Full Text PDFWeight loss with atogepant during the preventive treatment of migraine: A pooled analysis.
Cephalalgia
December 2024
AbbVie, North Chicago, IL, USA.
Background: Migraine is associated with obesity. These analyses evaluated weight change with atogepant used as a preventive migraine treatment.
Methods: Five atogepant clinical trials in adults with migraine (one phase 2b/3; four phase 3) were included: Three 12-week, randomized, placebo-controlled trials (episodic migraine: two; chronic migraine: one); one 40-week, open-label extension trial and one 52-week, standard care, randomized, long-term safety trial in episodic migraine.
Groundbreaking Research from NIDA Addressing the Challenges of the Opioid Epidemic.
J Med Toxicol
January 2025
OneFifteen, 257 Hopeland Street, Dayton, OH, 45417, USA.
The 2024 ACMT Ward and Ryan Donovan Memorial Fund lecture was presented by Dr. Nora Volkow, the director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH). This article in an edited version of her keynote address during ACMT's 2024 Annual Scientific Meeting.
View Article and Find Full Text PDFTreatment Modifications in Acute Coronary Syndrome Patients Treated with Ticagrelor: Insights from the FORCE-ACS Registry.
Thromb Haemost
October 2024
Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Article Synopsis
- The study investigates the frequency and reasons for changes in ticagrelor treatment among patients with acute coronary syndrome (ACS), revealing that many patients discontinue it prematurely.
- Data from over 4,200 patients showed that 26.7% had physician-recommended discontinuations and 20.1% had alterations in their treatment within a year.
- Treatment interruptions and disruptions significantly increased the risk of serious heart-related issues, while discontinuation and alterations did not show the same level of risk.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!